Biogen Signs On to Buy More EST Antibodies from MorphoSys | GenomeWeb

NEW YORK, Jan. 8 — MorphoSys said Tuesday that it would expand its drug target identification and validation partnership with Cambridge, Mass.-based Biogen.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.